CN102268457B - Alpha-fetoprotein (AFP) recombinant adeno associated virus, and construction method and application thereof - Google Patents
Alpha-fetoprotein (AFP) recombinant adeno associated virus, and construction method and application thereof Download PDFInfo
- Publication number
- CN102268457B CN102268457B CN201110125683XA CN201110125683A CN102268457B CN 102268457 B CN102268457 B CN 102268457B CN 201110125683X A CN201110125683X A CN 201110125683XA CN 201110125683 A CN201110125683 A CN 201110125683A CN 102268457 B CN102268457 B CN 102268457B
- Authority
- CN
- China
- Prior art keywords
- afp
- raav
- plasmid
- gene
- viral vectors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000702421 Dependoparvovirus Species 0.000 title claims abstract description 48
- 238000010276 construction Methods 0.000 title claims abstract description 9
- 108010026331 alpha-Fetoproteins Proteins 0.000 title abstract description 8
- 102000013529 alpha-Fetoproteins Human genes 0.000 title abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 64
- 210000004027 cell Anatomy 0.000 claims abstract description 59
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 49
- 201000007270 liver cancer Diseases 0.000 claims abstract description 14
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims description 134
- 239000013603 viral vector Substances 0.000 claims description 63
- 239000013612 plasmid Substances 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 32
- 241000700605 Viruses Species 0.000 claims description 31
- 239000012634 fragment Substances 0.000 claims description 28
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 239000002299 complementary DNA Substances 0.000 claims description 24
- 108091008146 restriction endonucleases Proteins 0.000 claims description 19
- 102000007469 Actins Human genes 0.000 claims description 17
- 108010085238 Actins Proteins 0.000 claims description 17
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 238000012408 PCR amplification Methods 0.000 claims description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 210000004907 gland Anatomy 0.000 claims description 11
- 210000001616 monocyte Anatomy 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 238000001890 transfection Methods 0.000 claims description 10
- 101150044789 Cap gene Proteins 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 7
- 101150013996 LIP gene Proteins 0.000 claims description 6
- 230000004544 DNA amplification Effects 0.000 claims description 5
- 108010042407 Endonucleases Proteins 0.000 claims description 5
- 102000004533 Endonucleases Human genes 0.000 claims description 5
- 101150055123 afp gene Proteins 0.000 claims description 5
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 4
- 210000000605 viral structure Anatomy 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 238000013326 plasmid cotransfection Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 65
- 108091007433 antigens Proteins 0.000 abstract description 47
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract description 44
- 210000004881 tumor cell Anatomy 0.000 abstract description 15
- 238000002474 experimental method Methods 0.000 abstract description 7
- 230000012010 growth Effects 0.000 abstract description 6
- 230000003211 malignant effect Effects 0.000 abstract description 4
- 239000013598 vector Substances 0.000 abstract description 3
- 239000012636 effector Substances 0.000 abstract description 2
- 210000000987 immune system Anatomy 0.000 abstract description 2
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 description 34
- 239000000427 antigen Substances 0.000 description 23
- 102000036639 antigens Human genes 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 10
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 229940041181 antineoplastic drug Drugs 0.000 description 9
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000000246 agarose gel electrophoresis Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000013016 damping Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000002845 virion Anatomy 0.000 description 5
- 102100035793 CD83 antigen Human genes 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 101150066583 rep gene Proteins 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 101710192602 Latent membrane protein 1 Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000010455 autoregulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4634—Antigenic peptides; polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464481—Alpha-feto protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464494—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464495—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/52—Intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/58—Prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110125683XA CN102268457B (en) | 2007-04-23 | 2008-04-23 | Alpha-fetoprotein (AFP) recombinant adeno associated virus, and construction method and application thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710097935.6 | 2007-04-23 | ||
CN200710097935 | 2007-04-23 | ||
CN201110125683XA CN102268457B (en) | 2007-04-23 | 2008-04-23 | Alpha-fetoprotein (AFP) recombinant adeno associated virus, and construction method and application thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008800129496A Division CN101680002B (en) | 2007-04-23 | 2008-04-23 | A series of recombinant adeno-associated viral vectors, construction methods and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102268457A CN102268457A (en) | 2011-12-07 |
CN102268457B true CN102268457B (en) | 2013-06-26 |
Family
ID=39875079
Family Applications (16)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011101256327A Active CN102268454B (en) | 2007-04-23 | 2008-04-23 | Prostate specific membrane antigen (PSMA) recombinant adeno-associated virus vector and its construction method and use |
CN2011101256971A Active CN102268458B (en) | 2007-04-23 | 2008-04-23 | BA46 recombinant adeno-associated virus vector and construction method and application thereof |
CN2011101256651A Active CN102268453B (en) | 2007-04-23 | 2008-04-23 | LMP-1 recombinant adeno-associated virus (rAAV) vector and construction method as well as application thereof |
CNA2008100932246A Withdrawn CN101307330A (en) | 2007-04-23 | 2008-04-23 | BA46 recombinant adeno-associated virus, construction process thereof and applications |
CNA2008100932231A Withdrawn CN101307329A (en) | 2007-04-23 | 2008-04-23 | Her-2/neu recombinant adeno-associated virus, construction process thereof and applications |
CNA2008100932227A Withdrawn CN101307328A (en) | 2007-04-23 | 2008-04-23 | CK19 recombinant adeno-associated virus, construction process thereof and applications |
CNA2008100932212A Withdrawn CN101307327A (en) | 2007-04-23 | 2008-04-23 | CEA recombinant adeno-associated virus, construction process thereof and applications |
CNA2008100932208A Withdrawn CN101307326A (en) | 2007-04-23 | 2008-04-23 | PSA recombinant adeno-associated virus, construction process thereof and applications |
CN2008800129496A Active CN101680002B (en) | 2007-04-23 | 2008-04-23 | A series of recombinant adeno-associated viral vectors, construction methods and uses thereof |
CNA2008100932265A Withdrawn CN101255442A (en) | 2007-04-23 | 2008-04-23 | LMP-1 recombinant gland related viral vectors as well as construction method and uses thereof |
CNA2008100932250A Withdrawn CN101255441A (en) | 2007-04-23 | 2008-04-23 | AFP recombinant gland related viral vectors as well as construction method and uses thereof |
CN2011101256030A Active CN102277384B (en) | 2007-04-23 | 2008-04-23 | PSA recombinant adeno-associated viral vector and its construction method and application |
CN201110125683XA Active CN102268457B (en) | 2007-04-23 | 2008-04-23 | Alpha-fetoprotein (AFP) recombinant adeno associated virus, and construction method and application thereof |
CN2011101256609A Active CN102268456B (en) | 2007-04-23 | 2008-04-23 | Her-2/neu recombinant adeno-associated virus vector and construction method as well as application thereof |
CN2011101256435A Active CN102268455B (en) | 2007-04-23 | 2008-04-23 | CEA (chorioembryonic antigen) recombinant adeno-associated viral vector, constructing method thereof and application thereof |
CNA2008100932195A Withdrawn CN101307325A (en) | 2007-04-23 | 2008-04-23 | PSMA recombinant adeno-associated virus, construction process thereof and applications |
Family Applications Before (12)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011101256327A Active CN102268454B (en) | 2007-04-23 | 2008-04-23 | Prostate specific membrane antigen (PSMA) recombinant adeno-associated virus vector and its construction method and use |
CN2011101256971A Active CN102268458B (en) | 2007-04-23 | 2008-04-23 | BA46 recombinant adeno-associated virus vector and construction method and application thereof |
CN2011101256651A Active CN102268453B (en) | 2007-04-23 | 2008-04-23 | LMP-1 recombinant adeno-associated virus (rAAV) vector and construction method as well as application thereof |
CNA2008100932246A Withdrawn CN101307330A (en) | 2007-04-23 | 2008-04-23 | BA46 recombinant adeno-associated virus, construction process thereof and applications |
CNA2008100932231A Withdrawn CN101307329A (en) | 2007-04-23 | 2008-04-23 | Her-2/neu recombinant adeno-associated virus, construction process thereof and applications |
CNA2008100932227A Withdrawn CN101307328A (en) | 2007-04-23 | 2008-04-23 | CK19 recombinant adeno-associated virus, construction process thereof and applications |
CNA2008100932212A Withdrawn CN101307327A (en) | 2007-04-23 | 2008-04-23 | CEA recombinant adeno-associated virus, construction process thereof and applications |
CNA2008100932208A Withdrawn CN101307326A (en) | 2007-04-23 | 2008-04-23 | PSA recombinant adeno-associated virus, construction process thereof and applications |
CN2008800129496A Active CN101680002B (en) | 2007-04-23 | 2008-04-23 | A series of recombinant adeno-associated viral vectors, construction methods and uses thereof |
CNA2008100932265A Withdrawn CN101255442A (en) | 2007-04-23 | 2008-04-23 | LMP-1 recombinant gland related viral vectors as well as construction method and uses thereof |
CNA2008100932250A Withdrawn CN101255441A (en) | 2007-04-23 | 2008-04-23 | AFP recombinant gland related viral vectors as well as construction method and uses thereof |
CN2011101256030A Active CN102277384B (en) | 2007-04-23 | 2008-04-23 | PSA recombinant adeno-associated viral vector and its construction method and application |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011101256609A Active CN102268456B (en) | 2007-04-23 | 2008-04-23 | Her-2/neu recombinant adeno-associated virus vector and construction method as well as application thereof |
CN2011101256435A Active CN102268455B (en) | 2007-04-23 | 2008-04-23 | CEA (chorioembryonic antigen) recombinant adeno-associated viral vector, constructing method thereof and application thereof |
CNA2008100932195A Withdrawn CN101307325A (en) | 2007-04-23 | 2008-04-23 | PSMA recombinant adeno-associated virus, construction process thereof and applications |
Country Status (2)
Country | Link |
---|---|
CN (16) | CN102268454B (en) |
WO (1) | WO2008128440A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101775375B (en) * | 2009-07-31 | 2013-04-10 | 华中科技大学同济医学院附属同济医院 | Preparation method of recombinant adeno-associated viruses containing EB virus latent membrane protein 1 and 2 genes and application thereof |
CN101638655B (en) * | 2009-09-03 | 2011-05-04 | 杭州安倍生物科技有限公司 | Carcinoembryonic antigen positive cell targeted gene expression element CPE and application thereof |
CN105316361B (en) * | 2014-08-01 | 2017-11-28 | 广东拓谱康生物科技有限公司 | Carry HPV 16 saltant type E7m58The recombined glandulae correlation viral vectors and its construction method of antigen gene and application |
CN105177048B (en) * | 2014-08-12 | 2018-02-02 | 广东拓谱康生物科技有限公司 | Carry HPV 16 multipoint mutation type E7mmThe recombined glandulae correlation viral vectors and its construction method of antigen gene and application |
CN105018525B (en) * | 2014-08-12 | 2017-06-13 | 广东拓谱康生物科技有限公司 | Carry HPV 16 saltant type E7m91The recombined glandulae correlation viral vectors and its construction method of antigen gene and application |
CN105177047B (en) * | 2014-08-12 | 2018-02-02 | 广东拓谱康生物科技有限公司 | Carry HPV 16 saltant type E7m94The recombined glandulae correlation viral vectors and its construction method of antigen gene and application |
CN104830800A (en) * | 2015-05-05 | 2015-08-12 | 杨光华 | DC cell based on PSMA antigen, targeting immune cell population, preparation method and applications thereof |
CN104830780A (en) * | 2015-05-05 | 2015-08-12 | 杨光华 | DC cell based on BA46 antigen and targeting immune cell population, and preparation method and application thereof |
CN104830782A (en) * | 2015-05-05 | 2015-08-12 | 杨光华 | CK19 antigen based DC cell and targeting immune cell population, and preparation method and application thereof |
CN105087649B (en) * | 2015-06-17 | 2018-10-02 | 深圳益世康宁生物科技有限公司 | The recombined glandulae correlation viral vectors and construction method of carrying MUC-1 antigen genes and application |
CN105087648B (en) * | 2015-06-17 | 2018-05-25 | 深圳益世康宁生物科技有限公司 | The recombined glandulae correlation viral vectors and construction method of carrying MAGE-A3 antigen genes and application |
CN105985984B (en) * | 2015-06-17 | 2018-10-02 | 深圳益世康宁生物科技有限公司 | The recombined glandulae correlation viral vectors and construction method of carrying PAP antigen genes and application |
CN105969804B (en) * | 2015-06-17 | 2018-10-02 | 深圳益世康宁生物科技有限公司 | A kind of recombined glandulae correlation viral vectors carrying SCC antigen genes and its construction method and application |
CN105087647B (en) * | 2015-06-17 | 2018-10-02 | 深圳益世康宁生物科技有限公司 | A kind of recombined glandulae correlation viral vectors carrying Survivin antigen genes and its construction method and application |
CN106591370A (en) * | 2015-10-19 | 2017-04-26 | 南京华贞生物医药科技有限公司 | Virus vector for treating autoimmune related diseases and diabetes, construction method and applications thereof |
CN106119231A (en) * | 2016-06-24 | 2016-11-16 | 安徽未名细胞治疗有限公司 | The CTL of a kind of tumor antigen PSA identifies epitope peptide and application thereof |
CN106282234B (en) * | 2016-08-05 | 2020-11-13 | 深圳前海美康医疗生物技术有限公司 | Recombinant adeno-associated virus vector carrying surface antigen S gene of human C-genotype hepatitis B virus and construction method and application thereof |
CN108546715A (en) * | 2018-01-19 | 2018-09-18 | 广东拓谱康生物科技有限公司 | A kind of LMP-2 recombined glandulae correlation viral vectors and its construction method and application |
CN108841867A (en) * | 2018-06-11 | 2018-11-20 | 北京安斯晨睿生物科技有限公司 | The recombined glandulae correlation viral vectors and its construction method of carrying SCC/BST2 mutant antigen gene and application |
CN108642085A (en) * | 2018-06-11 | 2018-10-12 | 北京安斯晨睿生物科技有限公司 | The recombined glandulae correlation viral vectors and its construction method of carrying BCMA mutant antigen genes and application |
CN108753825A (en) * | 2018-06-11 | 2018-11-06 | 北京安斯晨睿生物科技有限公司 | The recombined glandulae correlation viral vectors and its construction method of carrying HER2/ERBB mutant antigen genes and application |
CN108893490A (en) * | 2018-07-25 | 2018-11-27 | 北京安斯晨睿生物科技有限公司 | The recombined glandulae correlation viral vectors and its construction method of carrying CEACAM8 mutant antigen gene and application |
CN109234314B (en) * | 2018-10-16 | 2022-06-07 | 汉恒生物科技(上海)有限公司 | Adeno-associated virus recombinant vector for knocking out CXCL12 gene and construction method and application thereof |
CN110885855A (en) * | 2018-11-02 | 2020-03-17 | 深圳益世康宁生物科技有限公司 | Recombinant adeno-associated virus vector carrying sperm protein 17 antigen gene and application value thereof |
CN110684800B (en) * | 2018-11-02 | 2020-11-03 | 深圳益世康宁生物科技有限公司 | Recombinant adeno-associated virus vector carrying tumor-testis antigen 10 gene and application value thereof |
CN113196057A (en) * | 2018-11-09 | 2021-07-30 | 积水医疗株式会社 | Method for detecting viral liver cancer |
CN111647606B (en) * | 2020-08-06 | 2020-11-27 | 北京翊博普惠生物科技发展有限公司 | DC cell and CTL cell of targeted AFP whole antigen, and preparation method and application thereof |
KR20230085912A (en) | 2020-10-15 | 2023-06-14 | 에보사이트 인코포레이티드 | Recombinant adeno-associated viral vector with CD14 promoter and use thereof |
CN116355058A (en) * | 2020-11-12 | 2023-06-30 | 天津大学 | EB virus antigen epitope and application thereof |
CN113416729B (en) * | 2021-05-18 | 2022-11-22 | 遵义医科大学附属医院 | shRNA and cDNA of liver target regulation alpha fetoprotein gene and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1252840A (en) * | 1997-03-03 | 2000-05-10 | 卡里唐公司 | Adenovirus vector specific for cells expressing alpha fetoprotein and methods of use thereof |
US6652850B1 (en) * | 1993-09-13 | 2003-11-25 | Aventis Pharmaceuticals Inc. | Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173414A (en) * | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
CN100402655C (en) * | 2005-03-17 | 2008-07-16 | 中山大学中山医学院科技开发中心 | Method for constructing human neurenergen-3 receptor gene recombination adenovirus |
-
2008
- 2008-04-23 CN CN2011101256327A patent/CN102268454B/en active Active
- 2008-04-23 CN CN2011101256971A patent/CN102268458B/en active Active
- 2008-04-23 CN CN2011101256651A patent/CN102268453B/en active Active
- 2008-04-23 CN CNA2008100932246A patent/CN101307330A/en not_active Withdrawn
- 2008-04-23 CN CNA2008100932231A patent/CN101307329A/en not_active Withdrawn
- 2008-04-23 CN CNA2008100932227A patent/CN101307328A/en not_active Withdrawn
- 2008-04-23 CN CNA2008100932212A patent/CN101307327A/en not_active Withdrawn
- 2008-04-23 CN CNA2008100932208A patent/CN101307326A/en not_active Withdrawn
- 2008-04-23 CN CN2008800129496A patent/CN101680002B/en active Active
- 2008-04-23 WO PCT/CN2008/000835 patent/WO2008128440A1/en active Application Filing
- 2008-04-23 CN CNA2008100932265A patent/CN101255442A/en not_active Withdrawn
- 2008-04-23 CN CNA2008100932250A patent/CN101255441A/en not_active Withdrawn
- 2008-04-23 CN CN2011101256030A patent/CN102277384B/en active Active
- 2008-04-23 CN CN201110125683XA patent/CN102268457B/en active Active
- 2008-04-23 CN CN2011101256609A patent/CN102268456B/en active Active
- 2008-04-23 CN CN2011101256435A patent/CN102268455B/en active Active
- 2008-04-23 CN CNA2008100932195A patent/CN101307325A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6652850B1 (en) * | 1993-09-13 | 2003-11-25 | Aventis Pharmaceuticals Inc. | Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity |
CN1252840A (en) * | 1997-03-03 | 2000-05-10 | 卡里唐公司 | Adenovirus vector specific for cells expressing alpha fetoprotein and methods of use thereof |
Non-Patent Citations (3)
Title |
---|
张佑彬 等.携带抑癌基因的重组腺相关病毒载体的构建及病毒包装滴定方法探讨.《中华医学杂志》.2002,第82卷(第8期),564-567. * |
张明满 等.靶向肝癌细胞的重组腺相关病毒载体的构建.《中国普外基础与临床杂志》.2005,第12卷(第2期),142-146. * |
李志辉 等.人肝癌特异性HSV-TK/ GCV 重组腺病毒相关病毒质粒的构建与研究.《中国普外基础与临床杂志》.2004,第11卷(第3期),234-237. * |
Also Published As
Publication number | Publication date |
---|---|
CN101680002B (en) | 2011-11-23 |
CN101307329A (en) | 2008-11-19 |
CN101307325A (en) | 2008-11-19 |
CN102268455B (en) | 2013-09-18 |
CN102268458A (en) | 2011-12-07 |
CN101255441A (en) | 2008-09-03 |
CN101307327A (en) | 2008-11-19 |
CN102268456A (en) | 2011-12-07 |
CN102268453B (en) | 2013-04-03 |
CN102277384B (en) | 2013-06-26 |
CN102268454A (en) | 2011-12-07 |
CN101307326A (en) | 2008-11-19 |
CN102268455A (en) | 2011-12-07 |
CN102268456B (en) | 2013-02-06 |
CN102268457A (en) | 2011-12-07 |
CN101680002A (en) | 2010-03-24 |
CN102268454B (en) | 2013-07-24 |
CN102268458B (en) | 2013-04-03 |
CN101255442A (en) | 2008-09-03 |
WO2008128440A1 (en) | 2008-10-30 |
CN101307328A (en) | 2008-11-19 |
CN101307330A (en) | 2008-11-19 |
CN102277384A (en) | 2011-12-14 |
CN102268453A (en) | 2011-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102268457B (en) | Alpha-fetoprotein (AFP) recombinant adeno associated virus, and construction method and application thereof | |
CN105985984B (en) | The recombined glandulae correlation viral vectors and construction method of carrying PAP antigen genes and application | |
CN105087647B (en) | A kind of recombined glandulae correlation viral vectors carrying Survivin antigen genes and its construction method and application | |
CN105087648B (en) | The recombined glandulae correlation viral vectors and construction method of carrying MAGE-A3 antigen genes and application | |
WO2016015684A1 (en) | Nrecombinant adeno-associated virus vector carrying human papillomavirus type 16 mutation e7 antigen gene, construction method therefor, and application thereof | |
CN105018525B (en) | Carry HPV 16 saltant type E7m91The recombined glandulae correlation viral vectors and its construction method of antigen gene and application | |
CN105177048B (en) | Carry HPV 16 multipoint mutation type E7mmThe recombined glandulae correlation viral vectors and its construction method of antigen gene and application | |
CN105087649B (en) | The recombined glandulae correlation viral vectors and construction method of carrying MUC-1 antigen genes and application | |
CN108546715A (en) | A kind of LMP-2 recombined glandulae correlation viral vectors and its construction method and application | |
CN105969804B (en) | A kind of recombined glandulae correlation viral vectors carrying SCC antigen genes and its construction method and application | |
CN105316361B (en) | Carry HPV 16 saltant type E7m58The recombined glandulae correlation viral vectors and its construction method of antigen gene and application | |
CN105177047B (en) | Carry HPV 16 saltant type E7m94The recombined glandulae correlation viral vectors and its construction method of antigen gene and application | |
CN110684800B (en) | Recombinant adeno-associated virus vector carrying tumor-testis antigen 10 gene and application value thereof | |
CN106282234A (en) | The recombined glandulae correlation viral vectors of the surface antigen S gene of carrier's C genotype hepatitis B virus and construction method thereof and application | |
CN110885855A (en) | Recombinant adeno-associated virus vector carrying sperm protein 17 antigen gene and application value thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN IMMUCLIN BIOMED, INC. Free format text: FORMER OWNER: HEALTH POWER BIOMED (TIANJIN) INC. Effective date: 20121121 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 300457 HANGU, TIANJIN TO: 518057 SHENZHEN, GUANGDONG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20121121 Address after: 518057 Guangdong Province, Shenzhen high tech Zone of Nanshan District City, North Beihuan Road Song Ping Road No. 1 building fifteen South Liteon room 1503 Applicant after: Health-Power Biological Medical Technology (Tianjin) Co., Ltd. Address before: Thirteen Tianjin building, 300457 / F, experimental building, Tianjin international biological medicine Joint Research Institute, 220 Dongting Road, Tianjin Development Zone, S1306 Applicant before: Health-Power Biological Medical Technology (Tianjin) Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20111207 Assignee: Hebei Life Origin Biotechnology Co., Ltd. Assignor: Health-Power Biological Medical Technology (Tianjin) Co., Ltd. Contract record no.: 2015130000081 Denomination of invention: AFP recombinant gland related viral vectors as well as construction method and uses thereof Granted publication date: 20130626 License type: Exclusive License Record date: 20150608 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180416 Address after: 250101 room 805, block 1, R & D platform area, Ji'nan drug Valley, 1, north section of gang Xing three road, Ji'nan High-tech Zone, Shandong, China, 1 Patentee after: Shandong Yi Shi Li Bang Biotechnology Co., Ltd. Address before: 518057 Guangdong Province, Shenzhen high tech Zone of Nanshan District City, North Beihuan Road Song Ping Road No. 1 building fifteen South Liteon room 1503 Patentee before: Health-Power Biological Medical Technology (Tianjin) Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190111 Address after: 518000 South Mountain Science Park, Shenzhen City, Guangdong Province Patentee after: Health-Power Biological Medical Technology (Tianjin) Co., Ltd. Address before: Room 805, Block A, Building 1, Yaogu R&D Platform Area, No. 1, North Section of Gangxing No. 3 Road, Comprehensive Bonded Zone, Jinan High-tech Zone, Shandong Province, 250101 Patentee before: Shandong Yi Shi Li Bang Biotechnology Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190916 Address after: 518000 Tongfang Information Port A Block 701, No. 11 Longshan Road, Songpingshan Community, Xili Street, Nanshan District, Shenzhen City, Guangdong Province Patentee after: Shenzhen Yishi Kangning Biomedical Development Co., Ltd. Address before: 518000 South Mountain Science Park, Shenzhen City, Guangdong Province Patentee before: Health-Power Biological Medical Technology (Tianjin) Co., Ltd. |